BUZZ-Inovio Pharmaceuticals: AstraZeneca buys rights to cancer immunotherapy
** Drug developer's shares up 18.3 pct at $7.68 premarket on cancer drug deal with AstraZeneca (NYSE: AZN - news)
** AstraZeneca signs up rights to Inovio's experimental immune system-boosting medicine
** Inovio to get $27.5 mln upfront, potential future payments of up to $700 mln, based on success of its INO-3112 immunotherapy
** AstraZeneca unit MedImmune to fund development costs
** AstraZeneca US-shares shares down 1.22 pct at $33.28 premarket